Zymeworks stock trades steady as Q2 2026 data frame the story

Zymeworks stock, listed on Nasdaq, is trading near its latest quote while investors weigh second-quarter 2026 revenue growth and ongoing losses against a biotech peer backdrop.

Zymeworks stock (ISIN CA98959U1084) is holding close to its latest visible quote, giving investors a stable price backdrop as they assess second-quarter 2026 operating figures and the broader biotech sentiment as of August 31, 2026.

Q2 2026 figures set the operating tone

For Zymeworks Inc., the most recent operating snapshot centers on second-quarter 2026 results, which remain the primary reference point for investors tracking revenue progress and profitability in the current year, according to an earlier overview of the company’s data context.

In that second-quarter 2026 frame, the company’s revenue development and loss profile continue to matter for sentiment, particularly as biotech peers with strong top-line growth but negative earnings have seen mixed share-price reactions in recent weeks, as highlighted by analysis of Hong Kong listed artificial intelligence group Z.AI, where first half 2026 revenue reached CNY 953.9 million alongside a net loss from continuing operations of CNY 4.4 billion over the trailing twelve months, creating a contrast for investors between growth and losses in high innovation sectors and underscoring that Zymeworks is not alone in balancing expansion against red inkaccording to a Simply Wall St analysis.

Market data and peer comparison for investors

As of August 31, 2026, a recent Zymeworks-focused article referencing real-time data shows a price snapshot of USD 28.31 on Nasdaq with a prior USD 28.27 level and a 2.55% move on the trading page, positioning the stock in the upper segment of its latest short-term trading range and providing a concrete reference level for investors ahead of the next catalystaccording to an earlier Ad Hoc News overview.

The same price context on that page ties Zymeworks to a Nasdaq listing under the ticker ZYME, placing it within the US biotech universe where market capitalization figures and 52-week ranges are central for risk assessment, even as detailed market-cap data and the full range are not enumerated in the compact quote snapshot but remain accessible to investors through the underlying trading view on the portalas referenced in the Ad Hoc News article.

Biotech business and innovation context

Zymeworks Inc. operates as a clinical-stage biotechnology company focusing on engineered therapeutic candidates, particularly in oncology and other serious diseases where complex biologics and antibody-based constructs are central to its research pipeline, positioning the firm among innovation-driven peers that rely heavily on clinical trial progress for valuation.

The broader innovation environment is illustrated by the case of Hong Kong listed technology group Z.AI, whose first half 2026 revenue jumped nearly 400% according to a report, with its Hong Kong listed shares rising 2.9% to HKD 1,230 at 04:55 GMT, showing how strong revenue growth and clear percentage moves can translate into share-price reactions in high innovation sectorsaccording to Investing.com.

Zymeworks therapeutic focus

A representative product concept for Zymeworks is its antibody-based therapeutic platform, which aims to deliver targeted treatment options in oncology by engineering molecules to achieve high specificity and efficacy while managing safety and tolerability profiles, making the product strategy heavily dependent on successful clinical trial milestones and regulatory interactions.

Stock level and investor lens

With Zymeworks stock at USD 28.31 as of August 31, 2026 on Nasdaq, investors currently view the share price in the context of the latest quarter’s data and a broader biotech sector in which high growth and persistent losses coexist, and where the relative position within each company’s 52-week range helps frame risk and potential upside.

Zymeworks stock key data

• Company: Zymeworks Inc.
• ISIN: CA98959U1084
• Ticker: ZYME
• Trading venue: NASDAQ
• Price (as of August 31, 2026): 28.31 USD
• Sector / Industry: Biotechnology / Pharmaceuticals
• Index membership: Nasdaq composite index universe